Soleus Capital is a healthcare investment firm specializing in innovative life sciences, including biotech, medtech, diagnostics, and genomics. The firm invests across the healthcare lifecycle, from developmental-stage companies to commercial enterprises, with a focus on generating superior risk-adjusted returns through catalyst-driven investing in complex and niche opportunities.
The firm's portfolio includes notable companies such as Freenome, Abcuro, and Antios Therapeutics. Soleus Capital typically participates in Series B to Series D funding rounds, with occasional investments in post-IPO equity. Their investment strategy emphasizes identifying unique value propositions within the healthcare sector, supporting companies that drive innovation and advancement in medical technologies and treatments.
Soleus Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments27
Current Portfolio Count18
Total Portfolio Exits2
Top Investment Stages
Series B11 (40.7%)
Series C8 (29.6%)
Series D5 (18.5%)
Post Ipo Equity3 (11.1%)
Stage Mix
Series B 41%Series C 30%Series D 19%Post Ipo Equity 11%
Concentration shown as share of disclosed investments by stage.
Soleus Capital - Classification
- Also Known As
- Soleus Capital Management, L.P.
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified